李群 周純香
[摘要]目的:探討IL-1β經(jīng)NK-kB通路對(duì)炎癥狀態(tài)下牙周膜干細(xì)胞成骨成分調(diào)控機(jī)制。方法:從正常牙周組織和慢性牙周炎組織采用組織消化和有限稀釋法獲取不同來(lái)源的人牙周膜干細(xì)胞(hPDLSCs),采用免疫細(xì)胞化學(xué)法和流式細(xì)胞儀檢測(cè)兩種源細(xì)胞表面標(biāo)志分子表達(dá),采用MTT和細(xì)胞周期檢測(cè)間充質(zhì)干細(xì)胞增殖能力;間充質(zhì)干細(xì)胞多向分化能力檢測(cè)采用成骨和成脂分化誘導(dǎo)。構(gòu)建IL-1β(l0ng/ml)模擬牙周炎癥微環(huán)境模型,加入NF-kB信號(hào)通路抑制劑BAY 11-7082,研究牙周膜干細(xì)胞缺失性功能研究。結(jié)果:體外有限稀釋法結(jié)果表明,兩種來(lái)源間充質(zhì)干細(xì)胞均具有自我更新能力,MTT和細(xì)胞周期檢測(cè)表明牙周炎組干細(xì)胞增殖能力優(yōu)于對(duì)照組,炎癥因子IL-1β處理的正常組牙周膜干細(xì)胞可激活NF-kB通路,在IL-1β處理同時(shí)加入BAY 11-7082后成骨有關(guān)基因及蛋白表達(dá)水平增加。結(jié)論:炎癥因子IL-1β可激活NF-kB信號(hào)通路,并且可抑制牙周膜干細(xì)胞向成骨分化;對(duì)NF-kB信號(hào)通路抑制后能夠明顯逆轉(zhuǎn)IL-1β導(dǎo)致的干細(xì)胞成骨分化能力降低。
[關(guān)鍵詞]IL-1β;NK-kB通路;牙周膜干細(xì)胞;炎癥微環(huán)境;成骨分化
[中圖分類(lèi)號(hào)]R780.2? ? [文獻(xiàn)標(biāo)志碼]A? ? [文章編號(hào)]1008-6455(2020)09-0095-05
Analysis of the Regulation Mechanism of IL-1β on Osteogenesis of Periodontal Ligament Stem Cells Via NK-kB Pathway
LI Qun1, ZHOU Chun-xiang2
(1.Department of Stomatology,the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha 410007,Hunan,China;2.Department of Stomatology,Yongzhou Central Hospital,Yongzhou 425000,Hunan,China)
Abstract: Objective? To investigate the regulation mechanism of IL-1β on the osteogenesis of periodontal ligament stem cells in inflammatory state by NK-kB pathway. Methods? Human periodontal ligament stem cells (hPDLSCs) from different periodontal tissues and chronic periodontitis tissues were obtained by tissue digestion and limiting dilution method. The expression of cell surface marker molecules was detected by immunocytochemistry and flow cytometry. At the level, the proliferation of mesenchymal stem cells was detected by MTT and cell cycle; the multi-directional differentiation ability of mesenchymal stem cells was induced by osteogenic and adipogenic differentiation. Subsequently, IL-1β (10ng/ml) was used to simulate the periodontal inflammatory microenvironment and the NF-kB signaling pathway inhibitor BAY 11-7082 was added to study the function of periodontal ligament stem cell deletion. Results? In vitro limiting dilution method showed that both mesenchymal stem cells had self-renewal ability. MTT and cell cycle assay showed that the proliferative ability of stem cells in periodontitis group was better than that in control group, and the normal group of periodontal ligament stem cells treated with inflammatory factor IL-1β. The NF-kB pathway can be activated, and the expression levels of osteogenic genes and proteins are increased after the addition of BAY 11-7082 to IL-1β treatment. Conclusion The inflammatory factor IL-1β can significantly activate the NF-kB signaling pathway and negatively regulate the osteogenic differentiation of periodontal ligament stem cells. Inhibition of NF-kB can effectively reverse the decline in osteogenic differentiation induced by IL-1β.
Key words: IL-1β; NK-kB pathway; periodontal ligament stem cells; inflammatory microenvironment; osteogenic differentiation
牙周病可引起牙周頜骨及結(jié)締組織萎縮缺損,缺損處骨骼及軟組織重建為近年口腔科研究的熱點(diǎn)。Seo等[1]在2004年由健康牙周組織體外培養(yǎng)分離出牙周膜干細(xì)胞。隨后Osawa[2]和Cetinkaya B[3]等研究證實(shí)炎癥牙周組織和牙髓中存在有關(guān)的干細(xì)胞存在。因此,牙周組織有關(guān)干細(xì)胞在牙周缺損修復(fù)中具有重要意義,且炎癥有關(guān)因子在干細(xì)胞修改作用中具有調(diào)節(jié)功能。炎癥對(duì)干細(xì)胞微環(huán)境穩(wěn)態(tài)具有破壞作用,對(duì)干細(xì)胞內(nèi)源性信號(hào)調(diào)控作用可能具有一定的影響[4]。因此,牙周炎導(dǎo)致的牙周結(jié)締組織萎縮可能與人牙周膜干細(xì)胞(Human periodontal ligament stem cells,hPDLSCs)生物學(xué)功能受炎癥因子影響相關(guān)。NK-кB在慢性牙周炎發(fā)展中為一個(gè)具有關(guān)鍵性炎癥調(diào)控者的作用,NK-кB信號(hào)通路激活可促進(jìn)TNF-α、IL-1β等炎癥因子的表達(dá),這些炎癥因子作為激動(dòng)劑可進(jìn)一步作用于NK-кB信號(hào)通路,增加該信號(hào)通路的活性[5]?;谏鲜鱿嚓P(guān)報(bào)道,本研究探討PDLSCs在炎癥狀態(tài)下NK-кB和IкB表達(dá)水平的變化以及Nk-KB信號(hào)通路對(duì)炎癥狀態(tài)下PDLSCs成骨分化的調(diào)控機(jī)制,以期為臨床治療慢性牙周炎提供一定的依據(jù)。
1? 資料和方法
1.1 主要試劑:抗STRO-1抗體(購(gòu)自美國(guó)R&D Systems公司),羊抗鼠熒光二抗(購(gòu)自中國(guó)Boster公司),ALP顯色試劑(購(gòu)自中國(guó)Beyotime公司),TRIzol Reagent(購(gòu)自美國(guó)Invitrogen公司),Real-time PCR試劑盒、逆轉(zhuǎn)錄試劑盒(購(gòu)自日本TaKaRa公司),抗人Runx2、β-actin抗體(購(gòu)自美國(guó)Abcam公司),鼠抗人二抗、辣根過(guò)氧化物酶標(biāo)記山羊抗小鼠/抗兔IgG(購(gòu)自中國(guó)博士德公司),IкBa抗體、β-IкBa抗體、HDAC-1抗體、BAY 11-7082(購(gòu)自美國(guó)Cell signaling公司),細(xì)胞核蛋白與胞漿蛋白抽提試劑盒(購(gòu)自美國(guó)Millipore公司)。
1.2 樣本收集:正常組樣本來(lái)源于筆者醫(yī)院口腔科門(mén)診正畸患者10例,年齡23~35歲;炎癥組樣本來(lái)源于筆者醫(yī)院口腔科門(mén)診治療的慢性牙周炎患者8例,年齡24~37歲。
1.3 實(shí)驗(yàn)方法
1.3.1 干細(xì)胞原代培養(yǎng)和克?。喝山M牙周組織進(jìn)行細(xì)胞原代培養(yǎng),然后采用有限稀釋法克隆培養(yǎng)牙周膜干細(xì)胞。本研究采用第3~4代多克隆干細(xì)胞。
1.3.2 干細(xì)胞表型分析
1.3.2.1 細(xì)胞免疫熒光法:取兩組處于對(duì)數(shù)生長(zhǎng)期的第3代細(xì)胞,用細(xì)胞免疫熒光法分析干細(xì)胞表面分子表達(dá)水平,陰性對(duì)照為PBS。
1.3.2.2 流式細(xì)胞儀分析:取兩組處于對(duì)數(shù)生長(zhǎng)期的第3代細(xì)胞(1×106個(gè)/ml),用流式細(xì)胞儀檢測(cè)熒光表達(dá)率。研究組細(xì)胞加入FITC、PE小鼠抗人CD14、CD29、CD44、CD45、CD90、CD105、CD146抗體,陰性對(duì)照加入FITC、PE標(biāo)記的小鼠IgG。
1.3.2.3 MTT和周期分析:取兩組處于對(duì)數(shù)生長(zhǎng)期的第3代細(xì)胞,運(yùn)用MTT法繪制生長(zhǎng)曲線(xiàn)。并取兩組處于對(duì)數(shù)生長(zhǎng)期的第3代細(xì)胞,處理后4℃保存以備進(jìn)行周期分析。
1.3.2.4 干細(xì)胞誘導(dǎo)分化實(shí)驗(yàn):取兩組處于對(duì)數(shù)生長(zhǎng)期的第3代細(xì)胞,分別進(jìn)行成骨誘導(dǎo)和成脂誘導(dǎo),并進(jìn)行礦化結(jié)節(jié)定量分析和脂滴定量分析。
1.3.3 Real-time RT-PCR檢測(cè)和Western blot檢測(cè):按照TRIZOL Reagent說(shuō)明書(shū)提取干細(xì)胞RNA,并測(cè)定純度,然后按照PrimeScriptTM RT-PCR kit試劑盒說(shuō)明合成cDNA,計(jì)算反轉(zhuǎn)錄體系所需RNA量。按照SYBR? Premix Ex TaqTM試劑盒說(shuō)明將反轉(zhuǎn)錄獲得的cDNA加入擴(kuò)增體系,置于CFX96TM Real-time System檢測(cè)。并對(duì)兩種經(jīng)成骨誘導(dǎo)干細(xì)胞蛋白用Western blot進(jìn)行檢測(cè)。
1.4 NF-кB信號(hào)通路研究:取正常組處于對(duì)數(shù)生長(zhǎng)期的第4代細(xì)胞分為對(duì)照組和誘導(dǎo)組。對(duì)照組采用成骨誘導(dǎo)液培養(yǎng)7d,誘導(dǎo)組使用含有IL-1β(10ng/ml)的成骨誘導(dǎo)液培養(yǎng)7d。棄培養(yǎng)基加入新鮮培養(yǎng)基培養(yǎng)1h后提取細(xì)胞RNA和胞質(zhì)/胞核蛋白,用Real-time RT-PCR和Western blot進(jìn)行檢測(cè)。
1.5 統(tǒng)計(jì)學(xué)分析:采用SPSS 20.0統(tǒng)計(jì)學(xué)軟件進(jìn)行統(tǒng)計(jì)分析;組間對(duì)比采用t檢驗(yàn)分析,當(dāng)P<0.05時(shí)差異具有統(tǒng)計(jì)學(xué)意義。
2? 結(jié)果
2.1 兩種來(lái)源PDLSCs細(xì)胞形態(tài)學(xué)觀(guān)察:對(duì)組織行原代培養(yǎng)3~8d后可見(jiàn)牙周膜組織塊邊緣存在牙周膜細(xì)胞爬出(見(jiàn)圖1A、D),大多數(shù)細(xì)胞鏡下形態(tài)為長(zhǎng)梭形或不規(guī)則形。采用有限稀釋法克隆培養(yǎng)干細(xì)胞8d即可出現(xiàn)細(xì)胞克隆,獲得正常組PDLSCs(見(jiàn)圖1B)和炎癥組PDLSCs(見(jiàn)圖1E)。倒置顯微鏡觀(guān)察,可見(jiàn)兩種來(lái)源細(xì)胞呈紡錘形(見(jiàn)圖1C、F)。兩種來(lái)源PDLSCs形態(tài)學(xué)無(wú)差異。
2.2 兩種來(lái)源PDLSCs細(xì)胞表型:兩種來(lái)源PDLSCs細(xì)胞行熒光化學(xué)分析顯示均表達(dá)Seto-1(見(jiàn)圖2)。經(jīng)流式細(xì)胞儀分析顯示,兩種來(lái)源細(xì)胞均表達(dá)CD29、CD44、CD90、CD105、CD146,但未表達(dá)CD14、CD31及CD45(見(jiàn)圖3)。
2.3 兩種來(lái)源PDLSCs細(xì)胞增殖能力比較:細(xì)胞周期檢測(cè)結(jié)果表明,正常組PDLSCs細(xì)胞G2+S期約占20.4%,炎癥組為36.1%;連續(xù)7d MTT檢測(cè)結(jié)果表明,兩種來(lái)源干細(xì)胞在培養(yǎng)第3天進(jìn)入對(duì)數(shù)生長(zhǎng)期,第4~5天為增殖期,第6天為平臺(tái)期,對(duì)數(shù)生長(zhǎng)期開(kāi)始兩種來(lái)源PDLSCs細(xì)胞增殖能力存在差異性。見(jiàn)圖4。
2.4 兩種來(lái)源PDLSCs分化能力對(duì)比:對(duì)兩種來(lái)源PDLSCs進(jìn)行成骨誘導(dǎo)7d,行ALP染色結(jié)果顯示,正常組PDLSCs染色較炎癥組深,茜素紅染色結(jié)果顯示,正常組PDLSCs礦化結(jié)節(jié)較炎癥組多;ALP定量與礦化結(jié)節(jié)定量分析表明正常組PDLSCs分化能力高于炎癥組(見(jiàn)圖5);Real-time PCR檢測(cè)表明,正常組PDLSCs的Runx2、ALP、OCN及Osterix mRNA表達(dá)高于炎癥組(見(jiàn)圖6);Western blot檢測(cè)結(jié)果表明,正常組PDLSCs Runx2和Osterix蛋白表達(dá)水平高于炎癥組。對(duì)兩種來(lái)源PDLSCs進(jìn)行成脂誘導(dǎo)14d,采用油紅O染色后結(jié)果顯示,兩組細(xì)胞脂滴形態(tài)無(wú)差別,但正常組PDLSCs脂滴數(shù)量及體積大于炎癥組;Real-time和Western blot結(jié)果表明,成脂誘導(dǎo)7d正常組PPAR-γ基因和蛋白表達(dá)較炎癥組高。
2.5 炎癥組PDLSCs成骨分化過(guò)程N(yùn)F-кB信號(hào)通路激活增強(qiáng):Western blot檢測(cè)結(jié)果表明,隨成骨誘導(dǎo)時(shí)間延長(zhǎng),Runx2蛋白表達(dá)水平隨之增加,且正常組PDLSCs Runx2蛋白表達(dá)水平高于炎癥組;兩種來(lái)源PDLSCs成骨誘導(dǎo)時(shí)p65和p-IкBα蛋白表達(dá)增加,而炎癥組PDLSCs胞質(zhì)p65和胞核p-IкBα蛋白表達(dá)水平高于正常組,見(jiàn)圖7。
2.6 阻斷NF-кB信號(hào)通路可促進(jìn)hPDLSCs成骨分化:Western blot檢測(cè)結(jié)果表明,加入BAY 11-7082可抑制hPDLSCs胞質(zhì)中p65和IкBα蛋白表達(dá),且胞核中p65表達(dá)也有所降低。見(jiàn)圖8。
2.7 IL-1β體外模擬炎癥微環(huán)境對(duì)PDLSCs成骨分化能力的影響:ALP、茜素紅及定量結(jié)果表明,IL-1β組ALP和茜素紅著色與對(duì)照組相比較淺,定量結(jié)果則一致(見(jiàn)圖9A~B)。Real-time RT-PCR檢測(cè)表明,成骨誘導(dǎo)7d,干預(yù)組Runx2和Osterix基因表達(dá)較對(duì)照組降低(見(jiàn)圖9C~D);Western blot檢測(cè)結(jié)果表明,IL-1β組Runx2和Osterix蛋白表達(dá)較對(duì)照組低。
2.8 IL-1β對(duì)PDLSCs的NF-кB通路影響:IL-1β組胞質(zhì)中p65和IкBα蛋白表達(dá)水平降低,但磷酸化IкBα水平上升;胞核內(nèi)p65表達(dá)水平與對(duì)照組對(duì)比增加(見(jiàn)圖10)。
3? 討論
目前,大量研究發(fā)現(xiàn)PDLSCs在牙周組織再生中具有重要作用[6-7],而在慢性炎癥中,牙周組織缺損與再生異常可能是因?yàn)镻DLSCs功能異常導(dǎo)致[8]。本研究收集牙周健康患者和牙周炎患者牙周膜,采用有限稀釋法進(jìn)行離體培養(yǎng)。實(shí)驗(yàn)結(jié)果表明,兩種不同來(lái)源PDLSCs細(xì)胞形態(tài)呈紡錘形,并且已螺旋簇集落生長(zhǎng),在形態(tài)學(xué)上無(wú)差異。則證實(shí)PDLSCs形態(tài)與炎癥無(wú)相關(guān)性,與有研究結(jié)果相符。目前,間充質(zhì)干細(xì)胞表面標(biāo)志物鑒定為細(xì)胞鑒定的主要方式,PDLSCs為間充質(zhì)干細(xì)胞的一種,與其他間充質(zhì)干細(xì)胞表面標(biāo)志物表達(dá)無(wú)差異,可特異性的表達(dá)Stro-1等分子標(biāo)記物[9]。兩種來(lái)源PDLSCs表面標(biāo)志物表達(dá)無(wú)差異,但炎癥組PDLSCs克隆形成率更高,則證實(shí)微環(huán)境改變對(duì)PDLSCs增殖能力具有調(diào)節(jié)作用。為了驗(yàn)證上述結(jié)果,本研究采用流式細(xì)胞儀檢測(cè)細(xì)胞周期與MTT檢測(cè)細(xì)胞增殖能力,研究結(jié)果表明炎癥組PDLSCs細(xì)胞增殖能力高于正常組。因此,可推測(cè)PDLSCs受到炎癥因子刺激后發(fā)生功能性缺陷,但細(xì)胞通過(guò)增強(qiáng)自我增殖能力達(dá)到功能性代償?shù)淖饔?。?dāng)然,也可能因炎癥作用促進(jìn)PDLSCs增殖,但尚需進(jìn)一步的研究證實(shí)。對(duì)兩種來(lái)源PDLSCs細(xì)胞進(jìn)行成骨成脂誘導(dǎo),兩種來(lái)源PDLSCs細(xì)胞礦化結(jié)節(jié)和脂滴出現(xiàn),由此證實(shí)兩種來(lái)源PDLSCs均具有多向分化能力,但炎癥組PDLSCs成骨與成脂分化能力較弱。成骨分化過(guò)程中,ALP活性越高表明細(xì)胞向成骨方向分化的程度越高,分泌礦化基質(zhì)的能力也越高。Runx2和Osterix為干細(xì)胞中重要的轉(zhuǎn)錄因子,Runx2和Osterix表達(dá)水平為成骨分化能力的反應(yīng)指標(biāo)。PDLSCs成骨誘導(dǎo)分化7d ALP染色和誘導(dǎo)21d茜素紅染色表明,正常組PDLSCs礦化能力高于炎癥組。除此之外,PDLSCs成骨誘導(dǎo)后,正常組PDLSCs成骨有關(guān)基因Runx2和Osterix表達(dá)水平與炎癥組相比較高。上述研究結(jié)果證實(shí)牙周炎來(lái)源PDLSCs成骨能力受損。對(duì)PDLSCs進(jìn)行成脂誘導(dǎo)14d,行油紅O染色證實(shí)正常組PDLSCs脂滴數(shù)量與炎癥組相比更多。成脂有關(guān)基因PPAR-γ在炎癥組PDLSCs表達(dá)水平低于正常組PDLSCs。上述研究證實(shí)炎癥組PDLSCs成脂分化能力較弱。
轉(zhuǎn)錄因子NF-кB在炎癥和免疫應(yīng)答中具有重要的作用[10-11]。對(duì)關(guān)節(jié)炎進(jìn)行研究發(fā)現(xiàn),采用特異性抑制劑IKK可抑制破骨細(xì)胞形成緩解炎癥導(dǎo)致的骨喪失,則表明NF-кB在炎性骨疾病中具有重要作用[12]。雖然NF-кB在破骨細(xì)胞形成中作用已證實(shí),但NF-кB在成骨細(xì)胞活性、骨形成等的作用研究較少。在本研究中,采用IкBα抑制劑BAY 11-7082能夠特異性阻斷NF-кB信號(hào)通路,可增正常組PDLSCs細(xì)胞增殖能力且對(duì)炎癥組PDLSCs增殖能力也有一定的促進(jìn)作用。說(shuō)明在炎癥條件下NF-кB信號(hào)通路被激活,進(jìn)而引起PDLSCs成骨分化能力降低。
慢性牙周炎患者齦溝液中的炎性因子水平高于正常人群,而牙周炎中主要的炎癥因子之一為IL-1β[13]。IL-1β可持續(xù)活化NF-кB,活化后可加重局部組織炎癥反應(yīng),且能夠通過(guò)各種信號(hào)通路抑制炎癥組PDLSCs向成骨分化。在NF-кB經(jīng)典信號(hào)通路中,活化的IKK磷酸化IкB特異性絲氨酸殘基使IкB磷酸化被降解。IкB被降解后,轉(zhuǎn)錄因子NF-кB可由蛋白復(fù)合體中釋放,并且由胞質(zhì)轉(zhuǎn)移至胞核,與DNA上的кB位點(diǎn)結(jié)合,活化NF-кB信號(hào)通路下游基因[14]。雖然,IL-1β調(diào)節(jié)作用較為復(fù)雜,且作用機(jī)制尚未明確,但可以肯定IL-1β促炎效果則主要為通過(guò)持續(xù)激活NF-кB發(fā)揮作用[15]。在本研究中,IL-1β處理的正常組PDLSCs成骨分化能力明顯降低,且p-IкBα及核內(nèi)p65表達(dá)水平升高,說(shuō)明IL-1β可抑制PDLSCs成骨分化可能是通過(guò)NF-кB通路介導(dǎo)發(fā)揮作用。這與葉煒等研究結(jié)果相似[16]。在PDLSCs細(xì)胞中加入IL-1β和BAY 11-7082可使炎癥組PDLSCs成骨分化能力有所恢復(fù)。證實(shí)NF-кB具有介導(dǎo)IL-1β對(duì)PDLSCs成骨分化的調(diào)節(jié)作用。
綜上所述,炎癥因子IL-1β可激活NF-kB信號(hào)通路,并且可抑制牙周膜干細(xì)胞向成骨分化;對(duì)NF-kB信號(hào)通路抑制后能夠明顯逆轉(zhuǎn)IL-1β導(dǎo)致的干細(xì)胞成骨分化能力降低。
[參考文獻(xiàn)]
[1]Seo BM,Miura M,Gronthos S,et al.Investigation of multipotent postnatalstem cells from human periodontal ligament[J].Lancet,2004,364(9429):149-155.
[2]Osawa Y,Kojika E,Hayashi Y,et al.Tumor necrosis factor-α-mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice[J]Hepatol Commun,2018,2(4):407-420.
[3]Ertugrul AS,Bozoglan A,Taspinar M.The effect of nonsurgical periodontal treatment on serum and gingival crevicular fluid markers in patients with atherosclerosis[J].Niger J Clin Pract,2017,20(3):361.
[4]Gao J,F(xiàn)an MM,Xiang G,et al.Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells[J].Cell Death Dis,2017,8(5):e2765.
[5]Zheng J,Kong C,Yang X,et al.Protein kinase C-α (PKCα) modulates cell apoptosis by stimulating nuclear translocation of NF-kappa-B p65 in urothelial cell carcinoma of the bladder[J].BMC Cancer,2017,17(1):432.
[6]趙璐,吳佩玲,于莉,等.TNF-α對(duì)根尖乳頭干細(xì)胞與牙周膜干細(xì)胞增殖活性影響的比較研究[J].中國(guó)美容醫(yī)學(xué),2016,25(1):34-37.
[7]Duan X,Lin Z,Lin X,et al.Study of platelet-rich fibrin combined with rat periodontal ligament stem cells in periodontal tissue regeneration[J].J Cell Mol Med,2018,22(2):1047-1055.
[8]Li Y,Wang ZM,Zhao Y,et al.Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: A case report and literature review[J].Medicine(Baltimore),2018,97(16):e0515.
[9]Mrozik K,Gronthos S,Shi S,et al.A method to isolate, purify, and characterize human periodontal ligament stem cells[M].USA:Humana Press,2017:413-427.
[10]Chen XX,Nie XK,Mao JM,et al.Perfluorooctane sulfonate mediates secretion of IL-1β through PI3K/AKT NF-кB pathway in astrocytes[J].Neurotoxicol Teratol,2018,67:65-75.
[11]Ma J,Sun X,Guo T.Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell[J].Cancer Manag Res,2017,9:481-493.
[12]Ribaldone DG.Periodontal health and coronary heart disease: a comment[J].Minerva Stomatol,2018,67(1):34-35.
[13]Theodoro LH,Assem NZ,Longo M,et al.Treatment of periodontitis in smokers with multiple sessions of antimicrobial photodynamic therapy or systemic antibiotics: a randomized clinical trial[J].Photodiagnosis Photodyn Ther,2018,22:217-222.
[14]Berezniakova AI,Cheremisina VF.4 and 6 interleukin's action in the pathogenesis of periodontitis, gingivitis and dental alveolitis[J].Wiad Lek,2017,70(5):910-912.
[15]Chandur PK,Todd Schoenbaum,Kirk E King,et al.Techniques to optimize color esthetics, bonding, and peri-implant tissue health with titanium implant abutments[J].Compend Contin Educ Dent,2018,39(2):110-119.
[16]葉煒,費(fèi)小明,湯郁,等.IL-1β預(yù)刺激骨髓間充質(zhì)干細(xì)胞通過(guò)NF-κB通路調(diào)節(jié)其成骨分化潛能[J].中國(guó)實(shí)驗(yàn)血液學(xué)雜志,2017,25(3):890-895.
[收稿日期]2019-12-23
本文引用格式:李群,周純香.IL-1β經(jīng)NK-kB通路對(duì)牙周膜干細(xì)胞成骨成分調(diào)控的機(jī)制研究[J].中國(guó)美容醫(yī)學(xué),2020,29(9):95-99.